NCT00701233: Botulinum toxin versus steroid injection for carpal tunnel syndrome

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Withdrawn

NCT00701233 is a University of Minnesota study of botulinum toxin versus steroid injection for carpal tunnel syndrome. The planned phase 2 trial would randomize 20 symptomatic adults to an intercarpal botulinum-toxin injection or triamcinolone with local anesthetic. Pain and a carpal-tunnel symptom questionnaire were to be assessed repeatedly through 12 months. 1 2

The registry version posted in April 2019 labels the study withdrawn. Its sample size is a proposed number, not verified actual enrollment. No measured treatment comparison was found in the inspected record. 1 2

This resolves the identifier: it is not an unknown or necessarily invalid trial number. However, it does not provide evidence that botulinum toxin relieves carpal tunnel symptoms or is preferable to steroid injection or surgery. The planned intervention describes research, not an injection recommendation. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00701233. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00701233. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.